Atuveciclib Racemate

产品说明书

Print
Chemical Structure| 1414943-88-6 同义名 : BAY-1143572 Racemate;Atuveciclib;BAY-1143572
CAS号 : 1414943-88-6
货号 : A908334
分子式 : C18H18FN5O2S
纯度 : 99%+
分子量 : 387.431
MDL号 : MFCD30502894
存储条件:

Pure form Keep in dark place,Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(271.02 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Atuveciclib (BAY-1143572) suppresses the growth of seven AML cell lines, both with and without MLL rearrangements, displaying a median IC50 value of 385 nM (ranging from 230 to 1100 nM) and triggers apoptosis[1]. Atuveciclib (BAY-1143572) exhibits potent and highly selective inhibitory activity against PTEFb/CDK9 kinase within the low nanomolar range, with a selectivity that is at least 50 times greater against other CDKs. It also demonstrates favorable selectivity over a range of non-CDK kinases and broad antiproliferative effects across various tumor cell lines, achieving sub-micromolar IC50 values. A concentration-dependent decrease in the phosphorylation of RNA polymerase II, along with subsequent reductions in MYC mRNA and protein levels, has been observed[2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02345382 Leukemia Phase 1 Completed - United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Columbia University Medical Center New York, New York, United States, 10032 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Germany Universitätsklinikum der Johann Wolfgang Goethe Universität Frankfurt, Hessen, Germany, 60596 Medizinische Fakultät Carl Gustav Carus Dresden, Sachsen, Germany, 01307 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.58mL

0.52mL

0.26mL

12.91mL

2.58mL

1.29mL

25.81mL

5.16mL

2.58mL

参考文献

[1]Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceed

[2]Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [